Key Highlights

  • Alvotech (NASDAQ:ALVO) was trading down 9.53% at USD 4.22 on Friday, November 13, 2026 in market data, implying a prior close near USD 4.66 (calculated from the quoted price and move).
  • Cash fell to USD 61.5 million at September 30, 2026 from USD 172.4 million at year-end 2025, while nine-month operating cash outflow was USD 205.6 million and borrowings were about USD 1.4 billion.
  • Full-year guidance of USD 650 million to USD 700 million in Revenue and USD 180 million to USD 220 million in EBITDA was maintained, but performance is now expected toward the lower end.
  • Nine-month revenue was USD 323.4 million, down 23.0% from USD 420.0 million, and the reported net loss was USD 140.7 million against a profit of USD 136.5 million a year earlier.

Results Land Two Days Before the Drop

Alvotech (NASDAQ:ALVO) reported nine-month results with a Business update on November 11, 2026, followed by a management webcast on November 12, and was trading down 9.53% at USD 4.22 in market data on Friday, November 13. No other company announcement was found, so the results are the likeliest context, though nothing found ties the drop to them. The screener's prior close is treated as the figure of record for the live session only. Alvotech develops and manufactures biosimilar medicines, which are copies of biologic drugs, selling through commercial partners, with Teva holding U.S. commercial rights to its Entyvio candidate.

Lower-End Guidance and a Thin Cash Balance

Third-quarter revenue was USD 111.6 million, down 2.0%, while product and service revenue rose 78.3% to USD 58.2 million. Adjusted EBITDA for the quarter was USD 31.5 million, up from USD 14.4 million, and the gross Margin was 54%. The USD 650 million to USD 700 million revenue guide implies fourth-quarter revenue of about USD 327 million to USD 377 million (calculated from nine-month revenue), so landing at the lower end still requires a large quarter. Total Equity was a Deficit of USD 267.3 million, and the company said fourth-quarter product deliveries are planned.

Pipeline Progress Against Balance Sheet Strain

The pipeline update was constructive. The FDA accepted the application for AVT80, a proposed Entyvio biosimilar, while a first known worldwide filing was made for an aflibercept 8 mg biosimilar with Advanz Pharma, and the FDA approved a Reykjavik process that more than doubles output per batch. Against that, cash of USD 61.5 million is small next to about USD 1.4 billion of borrowings and a nine-month cash burn of USD 205.6 million, so financing is a risk. Investor conferences run from November 17 to November 25, and the next results are due on March 10, 2027.

Where Things Stand

The most direct explanation is the November 11 update, in which guidance was kept but shifted toward the lower end while cash dropped, though that link is unconfirmed. Alvotech (NASDAQ:ALVO) was trading down 9.53% at USD 4.22, with a calculated Market Value near USD 1.5 billion on about 356.9 million shares from a possibly stale page. The pipeline is moving, with an FDA acceptance and new partnerships, yet nine-month revenue is down 23.0% and cash is thin. Markers to watch are the November 17 and 18 investor conferences, fourth-quarter deliveries and any financing.